{
    "organizations": [],
    "uuid": "16ef1709b80eb0cbaa838de0f6ef2142cba99393",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/08/globe-newswire-chembio-diagnostics-reports-fourth-quarter-and-full-year-2017-financial-results.html",
    "ord_in_thread": 0,
    "title": "Chembio Diagnostics Reports Full Financial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "MEDFORD, N.Y., March 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (\"POC\") diagnostic tests for infectious diseases, today reported the fourth quarter and full year ended December 31, 2017.\nRecent Accomplishments & Highlights\nAchieved total revenue of $24.0 million of which net product sales were $19.3 million for the full year 2017, increases of 34% and 41% respectively, over prior year Received $8.5 million 2018 purchase commitment from Bio-Manguinhos in Brazil for DPP® HIV Assays and DPP® Leishmania Assays Won three-year, $15.8 million total contract value tender from the Ethiopian Pharmaceuticals Fund and Supply Agency to deliver HIV STAT-PAK® Assays between 2018-2020 Received conditional award of $1.5 million to $4.9 million in 2018-2019 from UNICEF for DPP® Zika Systems Filed Premarket Approval Application for the DPP® HIV-Syphilis Assay and DPP® Micro Reader to the Food and Drug Administration, following completion of U.S. clinical trials Entered collaboration with AstraZeneca to develop a quantitative DPP® Assay to detect an undisclosed biomarker, from which Chembio will receive up to $2.9 million in R&D funding over 18 months Strengthened balance sheet with $11.0 million in net capital from underwritten public offering in February 2018\n“We demonstrated strong financial performance and meaningful progress toward our strategic and operational objectives during the fourth quarter and full year 2017. We are particularly pleased with the strong growth in total revenue and product sales,” said John Sperzel, Chembio’s Chief Executive Officer. “Our DPP® platform is a cornerstone from which we can build and launch a meaningful pipeline of products, and as we enter 2018, we are well positioned to continue executing on several additional milestones.”\nFourth Quarter 2017 Financial Results\nTotal revenues for the fourth quarter of 2017 were $6.0 million, an increase of 40.7% compared to the fourth quarter of 2016. Net product sales for the fourth quarter of 2017 were $4.9 million, an increase of 50.9% compared to the fourth quarter of 2016. License and royalty and R&D, milestone and grant revenues for the fourth quarter of 2017 were $1.1 million, an increase of 8.8% compared to the fourth quarter of 2016.\nProduct gross margin for the fourth quarter of 2017 was $1.4 million, an increase of 97.9% compared to the fourth quarter of 2016. Gross product margin percent for the fourth quarter of 2017 was 29.5% compared to 22.5% for the fourth quarter of 2016.\nOther costs and expenses, representing R&D and SG&A expenses, for the fourth quarter of 2017 were $4.6 million, an increase of 7.2% compared to the fourth quarter of 2016. The $0.3 million increase was primarily due to an increase in sales and marketing expenses and professional fees.\nNet loss for the fourth quarter of 2017 was $2.0 million, or $0.16 per diluted share, compared with a net loss of $2.6 million, or $0.21 per diluted share, for the fourth quarter of 2016.\nFull Year 2017 Financial Results\nTotal revenues for 2017 were $24.0 million, an increase of 34.4% compared to 2016. Net product sales for 2017 were $19.3 million, an increase of 41.2% compared to 2016. License and royalty and R&D, milestone and grant revenues in 2017 totaled $4.7 million, an increase of 12.0% compared to 2016.\nGross product margin for 2017 was $6.4 million, an increase of 50.2% compared to 2016, the $2.1 million increase was primarily due to increased product sales volume. Gross product margin percent for 2017 was 33.1% compared to 31.2% for 2016.\nOther costs and expenses, representing R&D and SG&A expenses in 2017 were $17.6 million, an increase of 9.7% compared to 2016. The $1.6 million increase was primarily due to an increase in sales and marketing expenses and professional fees.\nNet loss for 2017 was $6.4 million, or $0.52 per diluted share, compared with net loss of $13.3 million, or $1.26 per diluted share, in 2016.\nCash as of December 31, 2017 totaled $3.8 million.\nConference Call\nChembio will host a conference call today beginning at 4:30pm ET to discuss financial results and recent business highlights. Investors interested in listening to the call may do so by dialing (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. To listen to a live webcast, please visit the Investor Relations section of Chembio's website at www.chembio.com . Following the call, a reply will be available on the Investor Relations section of the company’s website for 90 days. A telephone replay will be available by dialing (877) 481-4010 from the U.S. or (919) 882-2331 from outside the U.S. using the conference ID: 26056 until 4:30pm ET on March 15, 2018.\nAbout Chembio Diagnostics\nChembio Diagnostics, Inc. develops, manufactures, licenses, and markets rapid diagnostic tests in the growing $8.0 billion POC testing market. Chembio‘s patented DPP® technology platform offers significant advantages over traditional POC lateral-flow technologies and provides the Company with a robust pipeline of business opportunities in the areas of sexually transmitted disease, tropical and fever disease, and technology collaborations.\nThe Company markets its products directly and through third-party distributors under the brand names: DPP®, STAT-PAK®, SURE CHECK®, and STAT-VIEW®.\nHeadquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Each of Chembio Diagnostic Systems Inc. and Chembio Diagnostics Malaysia Sdn Bhd is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com .\nForward-Looking Statements\nStatements contained herein that are not historical facts may be within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.\n(Tables to follow)\nInvestor Relations Contact\nLynn Pieper Lewis\nGilmartin Group\n(415) 937-5402\ninvestor@chembio.com\nCHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the three months ended For the years ended December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 REVENUES: Net product sales $ 4,869,205 $ 3,226,919 $ 19,322,302 $ 13,680,107 License and royalty revenue 263,902 315,835 741,534 449,685 R&D, milestone and grant revenue 854,965 712,122 3,951,591 3,739,049 TOTAL REVENUES 5,988,072 4,254,876 24,015,427 17,868,841 COSTS AND EXPENSES: Cost of product sales 3,433,309 2,501,490 12,921,157 9,417,505 Research and development expenses 2,520,646 2,162,071 8,555,381 8,427,554 Selling, general and administrative expenses 2,118,383 2,164,891 9,021,439 7,595,559 8,072,338 6,828,452 30,497,977 25,440,618 LOSS FROM OPERATIONS (2,084,266 ) (2,573,576 ) (6,482,550 ) (7,571,777 ) OTHER INCOME (EXPENSE): Interest income (2,471 ) 15,819 22,485 25,548 LOSS BEFORE INCOME TAXES (2,086,737 ) (2,557,757 ) (6,460,065 ) (7,546,229 ) Income tax provision (benefit) (88,305 ) - (88,305 ) 5,800,818 NET LOSS $ (1,998,432 ) $ (2,557,757 ) $ (6,371,760 ) $ (13,347,047 ) Basic loss per share $ (0.16 ) $ (0.21 ) $ (0.52 ) $ (1.26 ) Diluted loss per share $ (0.16 ) $ (0.21 ) $ (0.52 ) $ (1.26 ) Weighted average number of shares outstanding, basic 12,505,844 12,026,847 12,300,031 10,622,331 Weighted average number of shares outstanding, diluted 12,505,844 12,026,847 12,300,031 10,622,331\nCHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS - ASSETS - December 31, 2017 December 31, 2016 CURRENT ASSETS: Cash $ 3,790,302 $ 10,554,464 Accounts receivable, net of allowance for doubtful accounts of $42,000 and $52,000 at December 31, 2017 and 2016, respectively 2,085,340 3,383,729 Inventories 4,423,618 3,335,188 Prepaid expenses and other current assets 554,383 840,145 TOTAL CURRENT ASSETS 10,853,643 18,113,526 FIXED ASSETS, net of accumulated depreciation 1,909,232 1,709,321 OTHER ASSETS: 3,853,146 752,389 TOTAL ASSETS $ 16,616,021 $ 20,575,236 - LIABILITIES AND STOCKHOLDERS’ EQUITY - TOTAL CURRENT LIABILITIES 3,096,303 3,405,650 TOTAL LIABILITIES 3,536,825 3,405,650 STOCKHOLDERS’ EQUITY: Common stock - $.01 par value; 100,000,000 shares authorized, 12,318,570 and 12,026,847 shares issued and outstanding for 2017 and 2016, respectively 123,185 120,268 62,821,288 60,721,783 Accumulated deficit (50,044,225 ) (43,672,465 ) Accumulated other comprehensive income 178,948 - TOTAL STOCKHOLDERS’ EQUITY 13,079,196 17,169,586 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 16,616,021 $ 20,575,236\nCHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES SUMMARY OF CONSOLIDATED CASH FLOWS For the years ended December 31, 2017 December 31, 2016 Net cash used in operating activities $ (5,034,515 ) $ (6,704,734 ) Net cash used in investing activities (1,876,954 ) (668,706 ) Net cash provided by financing activities 134,280 12,550,973 Effect of exhange rate changes on cash 13,027 - (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS $ (6,764,162 ) $ 5,177,533\nSource:Chembio Diagnostics, Inc.",
    "published": "2018-03-09T00:05:00.000+02:00",
    "crawled": "2018-03-09T02:01:34.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "medford",
        "march",
        "globe",
        "newswire",
        "chembio",
        "diagnostics",
        "nasdaq",
        "cemi",
        "leader",
        "poc",
        "diagnostic",
        "test",
        "infectious",
        "disease",
        "today",
        "reported",
        "fourth",
        "quarter",
        "full",
        "year",
        "ended",
        "december",
        "recent",
        "accomplishment",
        "highlight",
        "achieved",
        "total",
        "revenue",
        "million",
        "net",
        "product",
        "sale",
        "million",
        "full",
        "year",
        "increase",
        "respectively",
        "prior",
        "year",
        "received",
        "million",
        "purchase",
        "commitment",
        "brazil",
        "hiv",
        "assay",
        "leishmania",
        "assay",
        "million",
        "total",
        "contract",
        "value",
        "tender",
        "ethiopian",
        "pharmaceutical",
        "fund",
        "supply",
        "agency",
        "deliver",
        "hiv",
        "assay",
        "received",
        "conditional",
        "award",
        "million",
        "million",
        "unicef",
        "zika",
        "system",
        "filed",
        "premarket",
        "approval",
        "application",
        "assay",
        "micro",
        "reader",
        "food",
        "drug",
        "administration",
        "following",
        "completion",
        "clinical",
        "trial",
        "entered",
        "collaboration",
        "astrazeneca",
        "develop",
        "quantitative",
        "assay",
        "detect",
        "undisclosed",
        "biomarker",
        "chembio",
        "receive",
        "million",
        "r",
        "funding",
        "month",
        "strengthened",
        "balance",
        "sheet",
        "million",
        "net",
        "capital",
        "underwritten",
        "public",
        "offering",
        "february",
        "demonstrated",
        "strong",
        "financial",
        "performance",
        "meaningful",
        "progress",
        "toward",
        "strategic",
        "operational",
        "objective",
        "fourth",
        "quarter",
        "full",
        "year",
        "particularly",
        "pleased",
        "strong",
        "growth",
        "total",
        "revenue",
        "product",
        "sale",
        "said",
        "john",
        "sperzel",
        "chembio",
        "chief",
        "executive",
        "officer",
        "platform",
        "cornerstone",
        "build",
        "launch",
        "meaningful",
        "pipeline",
        "product",
        "enter",
        "well",
        "positioned",
        "continue",
        "executing",
        "several",
        "additional",
        "fourth",
        "quarter",
        "financial",
        "result",
        "total",
        "revenue",
        "fourth",
        "quarter",
        "million",
        "increase",
        "compared",
        "fourth",
        "quarter",
        "net",
        "product",
        "sale",
        "fourth",
        "quarter",
        "million",
        "increase",
        "compared",
        "fourth",
        "quarter",
        "license",
        "royalty",
        "r",
        "milestone",
        "grant",
        "revenue",
        "fourth",
        "quarter",
        "million",
        "increase",
        "compared",
        "fourth",
        "quarter",
        "product",
        "gross",
        "margin",
        "fourth",
        "quarter",
        "million",
        "increase",
        "compared",
        "fourth",
        "quarter",
        "gross",
        "product",
        "margin",
        "percent",
        "fourth",
        "quarter",
        "compared",
        "fourth",
        "quarter",
        "cost",
        "expense",
        "representing",
        "r",
        "sg",
        "expense",
        "fourth",
        "quarter",
        "million",
        "increase",
        "compared",
        "fourth",
        "quarter",
        "million",
        "increase",
        "primarily",
        "due",
        "increase",
        "sale",
        "marketing",
        "expense",
        "professional",
        "fee",
        "net",
        "loss",
        "fourth",
        "quarter",
        "million",
        "per",
        "diluted",
        "share",
        "compared",
        "net",
        "loss",
        "million",
        "per",
        "diluted",
        "share",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "total",
        "revenue",
        "million",
        "increase",
        "compared",
        "net",
        "product",
        "sale",
        "million",
        "increase",
        "compared",
        "license",
        "royalty",
        "r",
        "milestone",
        "grant",
        "revenue",
        "totaled",
        "million",
        "increase",
        "compared",
        "gross",
        "product",
        "margin",
        "million",
        "increase",
        "compared",
        "million",
        "increase",
        "primarily",
        "due",
        "increased",
        "product",
        "sale",
        "volume",
        "gross",
        "product",
        "margin",
        "percent",
        "compared",
        "cost",
        "expense",
        "representing",
        "r",
        "sg",
        "expense",
        "million",
        "increase",
        "compared",
        "million",
        "increase",
        "primarily",
        "due",
        "increase",
        "sale",
        "marketing",
        "expense",
        "professional",
        "fee",
        "net",
        "loss",
        "million",
        "per",
        "diluted",
        "share",
        "compared",
        "net",
        "loss",
        "million",
        "per",
        "diluted",
        "share",
        "cash",
        "december",
        "totaled",
        "million",
        "conference",
        "call",
        "chembio",
        "host",
        "conference",
        "call",
        "today",
        "beginning",
        "et",
        "discus",
        "financial",
        "result",
        "recent",
        "business",
        "highlight",
        "investor",
        "interested",
        "listening",
        "call",
        "may",
        "dialing",
        "outside",
        "listen",
        "live",
        "webcast",
        "please",
        "visit",
        "investor",
        "relation",
        "section",
        "chembio",
        "website",
        "following",
        "call",
        "reply",
        "available",
        "investor",
        "relation",
        "section",
        "company",
        "website",
        "day",
        "telephone",
        "replay",
        "available",
        "dialing",
        "outside",
        "using",
        "conference",
        "id",
        "et",
        "march",
        "chembio",
        "diagnostics",
        "chembio",
        "diagnostics",
        "develops",
        "manufacture",
        "license",
        "market",
        "rapid",
        "diagnostic",
        "test",
        "growing",
        "billion",
        "poc",
        "testing",
        "market",
        "chembio",
        "patented",
        "technology",
        "platform",
        "offer",
        "significant",
        "advantage",
        "traditional",
        "poc",
        "technology",
        "provides",
        "company",
        "robust",
        "pipeline",
        "business",
        "opportunity",
        "area",
        "sexually",
        "transmitted",
        "disease",
        "tropical",
        "fever",
        "disease",
        "technology",
        "collaboration",
        "company",
        "market",
        "product",
        "directly",
        "distributor",
        "brand",
        "name",
        "sure",
        "headquartered",
        "medford",
        "ny",
        "chembio",
        "licensed",
        "food",
        "drug",
        "administration",
        "fda",
        "well",
        "department",
        "agriculture",
        "usda",
        "certified",
        "global",
        "market",
        "international",
        "standard",
        "organization",
        "iso",
        "directive",
        "chembio",
        "diagnostic",
        "system",
        "chembio",
        "diagnostics",
        "malaysia",
        "sdn",
        "bhd",
        "subsidiary",
        "chembio",
        "diagnostics",
        "information",
        "please",
        "visit",
        "statement",
        "statement",
        "contained",
        "herein",
        "historical",
        "fact",
        "may",
        "within",
        "meaning",
        "security",
        "act",
        "amended",
        "statement",
        "include",
        "statement",
        "regarding",
        "intent",
        "belief",
        "current",
        "expectation",
        "company",
        "management",
        "statement",
        "estimate",
        "reflect",
        "management",
        "current",
        "view",
        "based",
        "certain",
        "assumption",
        "involve",
        "risk",
        "uncertainty",
        "actual",
        "result",
        "event",
        "performance",
        "may",
        "differ",
        "materially",
        "due",
        "number",
        "important",
        "factor",
        "dependent",
        "upon",
        "variety",
        "factor",
        "including",
        "limited",
        "chembio",
        "ability",
        "obtain",
        "additional",
        "financing",
        "obtain",
        "regulatory",
        "approval",
        "timely",
        "manner",
        "well",
        "demand",
        "chembio",
        "product",
        "chembio",
        "undertakes",
        "obligation",
        "publicly",
        "update",
        "reflect",
        "event",
        "circumstance",
        "occur",
        "date",
        "hereof",
        "reflect",
        "change",
        "chembio",
        "expectation",
        "regard",
        "occurrence",
        "unanticipated",
        "event",
        "factor",
        "may",
        "impact",
        "chembio",
        "success",
        "fully",
        "disclosed",
        "chembio",
        "recent",
        "public",
        "filing",
        "security",
        "exchange",
        "commission",
        "table",
        "follow",
        "investor",
        "relation",
        "contact",
        "lynn",
        "pieper",
        "lewis",
        "gilmartin",
        "group",
        "investor",
        "chembio",
        "diagnostics",
        "subsidiary",
        "consolidated",
        "statement",
        "operation",
        "unaudited",
        "three",
        "month",
        "ended",
        "year",
        "ended",
        "december",
        "december",
        "december",
        "december",
        "revenue",
        "net",
        "product",
        "sale",
        "license",
        "royalty",
        "revenue",
        "r",
        "milestone",
        "grant",
        "revenue",
        "total",
        "revenue",
        "cost",
        "expense",
        "cost",
        "product",
        "sale",
        "research",
        "development",
        "expense",
        "selling",
        "general",
        "administrative",
        "expense",
        "loss",
        "operation",
        "income",
        "expense",
        "interest",
        "income",
        "loss",
        "income",
        "tax",
        "income",
        "tax",
        "provision",
        "benefit",
        "net",
        "loss",
        "basic",
        "loss",
        "per",
        "share",
        "diluted",
        "loss",
        "per",
        "share",
        "weighted",
        "average",
        "number",
        "share",
        "outstanding",
        "basic",
        "weighted",
        "average",
        "number",
        "share",
        "outstanding",
        "diluted",
        "chembio",
        "diagnostics",
        "subsidiary",
        "consolidated",
        "balance",
        "sheet",
        "asset",
        "december",
        "december",
        "current",
        "asset",
        "cash",
        "account",
        "receivable",
        "net",
        "allowance",
        "doubtful",
        "account",
        "december",
        "respectively",
        "inventory",
        "prepaid",
        "expense",
        "current",
        "asset",
        "total",
        "current",
        "asset",
        "fixed",
        "asset",
        "net",
        "accumulated",
        "depreciation",
        "asset",
        "total",
        "asset",
        "liability",
        "stockholder",
        "equity",
        "total",
        "current",
        "liability",
        "total",
        "liability",
        "stockholder",
        "equity",
        "common",
        "stock",
        "par",
        "value",
        "share",
        "authorized",
        "share",
        "issued",
        "outstanding",
        "respectively",
        "accumulated",
        "deficit",
        "accumulated",
        "comprehensive",
        "income",
        "total",
        "stockholder",
        "equity",
        "total",
        "liability",
        "stockholder",
        "equity",
        "chembio",
        "diagnostics",
        "subsidiary",
        "summary",
        "consolidated",
        "cash",
        "flow",
        "year",
        "ended",
        "december",
        "december",
        "net",
        "cash",
        "used",
        "operating",
        "activity",
        "net",
        "cash",
        "used",
        "investing",
        "activity",
        "net",
        "cash",
        "provided",
        "financing",
        "activity",
        "effect",
        "exhange",
        "rate",
        "change",
        "cash",
        "decrease",
        "increase",
        "cash",
        "cash",
        "equivalent",
        "source",
        "chembio",
        "diagnostics",
        "inc"
    ]
}